NYSE - Nasdaq Real Time Price
USD
AbbVie Inc. (ABBV)
296.28
+5.49
(+1.89%)
As of 12:51:53 PM EDT. Market Open.
Trade AbbVie on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreAnalyst Insights
Top Analyst
Canaccord Genuity
88/100
Analyst Price Targets
Analyst Recommendations
-
Strong Buy
-
Buy
-
Hold
-
Underperform
-
Sell
Latest Rating
Date
10/23/2026
Analyst
Goldman Sachs
Rating Action
Maintains
Rating
Neutral
Price Action
Raises
Price Target
258 -> 294
Top Analysts
Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn more
Yahoo Finance’s Top Analysts section provides an objective scorecard to evaluate the accuracy of Wall Street analyst ratings and price targets.
Learn more| Analyst
|
Overall Score
|
Direction Score
|
Price Score
|
Latest Rating
|
Price Target
|
Date
|
|---|---|---|---|---|---|---|
|
Canaccord Genuity
|
88 | 91 | 100 | Buy
|
290 | 2026-08-04 |
|
Evercore ISI Group
|
68 | 67 | 100 | Outperform
|
260 | 2026-08-10 |
|
Cantor Fitzgerald
|
68 | 74 | 100 | Overweight
|
290 | 2026-10-09 |
|
RBC Capital
|
66 | 74 | 100 | Outperform
|
280 | 2026-10-13 |
|
Guggenheim
|
65 | 67 | 100 | Buy
|
288 | 2026-10-10 |
|
HSBC
|
64 | 64 | 93 | Buy
|
315 | 2026-09-10 |
|
Wells Fargo
|
63 | 70 | 100 | Overweight
|
300 | 2026-08-18 |
|
Piper Sandler
|
62 | 69 | 77 | Overweight
|
303 | 2026-08-20 |
|
Morgan Stanley
|
58 | 59 | 100 | Overweight
|
310 | 2026-10-07 |
|
Citigroup
|
57 | 58 | 84 | Neutral
|
260 | 2026-07-15 |
Rows per page
1-10 of 19
Upgrades & Downgrades
| Maintains | Goldman Sachs: Neutral to Neutral | 10/23/2026 |
| Maintains | Barclays: Overweight to Overweight | 10/21/2026 |
| Reiterates | RBC Capital: Outperform to Outperform | 10/13/2026 |
| Maintains | UBS: Neutral to Neutral | 10/9/2026 |
| Reiterates | Guggenheim: Buy to Buy | 10/9/2026 |
| Maintains | JP Morgan: Overweight to Overweight | 10/8/2026 |
